To probe the signaling networks in crizotinib-treated NB cells harboring the ALKF1174L mutation and amplified MYCN, we exposed Kelly NB cells (which express both genes) to crizotinib or vehicle for 6 hours and analyzed their gene expression profiles. The gene discussed is MYCN; the disease is neuroblastoma.